Natasha Schenk

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

Holger Eidtmann, Richard de Boer, Nigel Bundred et al. · Annals of Oncology · 2010 · 278 citations

Zoledronic Acid, Breast Oncology, Medicine +9

The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.

Holger Eidtmann, N.J. Bundred, Rebecca DeBoer et al. · Cancer Research · 2009 · 60 citations

Breast Oncology, Gynecology, Pharmacotherapy +21

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

Meagan B. Ryan, Bradley Quade, Natasha Schenk et al. · Cancer Discovery · 2024 · 33 citations · Full text

Ras-mapk Signaling Cascade, Ras–mapk Pathway, Glioma +19

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

Natasha Schenk, A. Lombart, A. Frassoladti et al. · European Journal of Cancer Supplements · 2007 · 31 citations

Bone Disease, Zoledronic Acid, Bone Loss +12

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

Adam Brufsky, Nigel Bundred, RE Coleman et al. · The Breast · 2007 · 15 citations

Bone Disease, Zoledronic Acid, Bone Loss +12